First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.

Descourt R, Chouaid C, Pérol M, Besse B, Greillier L, Bylicki O, Ricordel C, Guisier F, Gervais R, Schott R, Auliac JB, Robinet G, Decroisette C

Open source

DOI: 10.2217/fon-2020-1202
Published: 2021 Aug
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2217/fon-2020-1202,
  title = {First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.},
  author = {Descourt R and Chouaid C and Pérol M and Besse B and Greillier L and Bylicki O and Ricordel C and Guisier F and Gervais R and Schott R and Auliac JB and Robinet G and Decroisette C},
  year = {2021},
  journal = {Future oncology (London, England)},
  doi = {10.2217/fon-2020-1202},
  url = {https://doi.org/10.2217/fon-2020-1202}
}

RIS

TY  - JOUR
TI  - First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
AU  - Descourt R
AU  - Chouaid C
AU  - Pérol M
AU  - Besse B
AU  - Greillier L
AU  - Bylicki O
AU  - Ricordel C
AU  - Guisier F
AU  - Gervais R
AU  - Schott R
AU  - Auliac JB
AU  - Robinet G
AU  - Decroisette C
PY  - 2021
JO  - Future oncology (London, England)
DO  - 10.2217/fon-2020-1202
UR  - https://doi.org/10.2217/fon-2020-1202
ER  -

APA

R, D., C, C., M, P., B, B., L, G., O, B., C, R., F, G., R, G., R, S., JB, A., G, R., & C, D. (2021). First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.. Future oncology (London, England). https://doi.org/10.2217/fon-2020-1202

Source records

pubmed · retrieved 2026-09-25T11:28:31.661Z